Table 3.

Uni- and multivariate Cox regression analyses of PFS and OS.

Factors	Category	PFS				OS
		Univariate		Multivariate		Univariate		Multivariate
		HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Treatment line	First	0.440 (0.254–0.763)	.001	1.598 (0.527–4.850)	.408	0.410 (0.205–0.821)	.003	1.309 (0.764–0.570)	.526
TMB(muts/Mb)	≥10	0.490 (0.15–1.573)	.220			1.27e-0。8(0-Inf)	.035
PD-L1	CPS≥1	3.066(0.423–22.22)	.268			1.433 (0.196–10.49)	.723
NLR	≤2	0.616(0.357–1.064)	.079			0.492 (0.239–1.014)	.050
PLR	≤135	0.390(0.226–0.673)	<.001	0.898 (0.411–1.963)	.787	0.454 (0.242–0.850)	.012
LMR	≤2	1.988(0.996–3.968)	.05			2.401 (1.138–5.066)	.018
LDH	≤265	0.364(0.200–0.665)	<.001	0.280 (0.133–0.588)	.001	0.157 (0.079–0.312)	<.001	0.128 (0.059–0.2780)	<.001
Liver metastasis	Yes	4.483(2.429–8.275)	<.001	5.591 (1.71–18.285)	.004	4.151 (2.068–8.333)	<.001	5.011 (1.901–13.210)	.001
With radiotherapy	Yes	0.367(0.207–0.650)	<.001	0.560 (0.211–1.485)	.243	0.406 (0.202–0.814)	.009	0.961 (0.375–2.464)	.934

Abbreviations: PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; TMB, tumor mutational burden; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; LDH, lactate dehydrogenase.

P values in bold indicated statistically significant differences in multivariate analysis (P < .05).